|
Novel Targeted Therapy for Breast Cancer
|
1R43CA124179-01A1
|
$120,600
|
Serrero, Ginette
|
A AND G PHARMACEUTICAL, INC.
|
|
Operation and Maintenance of the Biological Data Processing System
|
N02CM522008-004
|
$909,596
|
KARPF, RONALD
|
ADDIS Incorporated
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
1R44CA124032-01A1
|
$101,130
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Aerosol Therapy for Lung Cancer
|
5R44CA096409-03
|
$371,115
|
Hansen, Brian
|
AEROPHASE, INC.
|
|
SYNTHESIS OF NON-GMP SMALL MOLECULES
|
N02CM622023-002
|
$125,000
|
POP, EMIL
|
ALCHEM LABORATORIES CORP
|
|
Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells
|
1R41CA126072-01A2
|
$115,953
|
QUINN, THOMAS
|
ALPHAMED, INC
|
|
Transgenic Plant Technology for Producing Therapeutic Recombinant Antibodies
|
5R44CA117211-03
|
$706,899
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
3U10CA021661-32S1
|
$300,000
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RADIATION THERAPY ONCOLOGY GROUP
|
5U10CA021661-32
|
$8,875,198
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Community Clinical Oncology Program Research Base
|
5U10CA037422-20
|
$1,483,085
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group-Statistical Center
|
5U10CA032115-26
|
$1,038,338
|
Sadek, Ramses
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Drug binding microprotein domains for targeted delivery of cytotoxic drugs
|
1R43CA128137-01
|
$108,284
|
Schellenberger, Volker
|
AMUNIX, INC.
|
|
Novel c-Met and Tie-2 antagonists against human glioma
|
1R43CA128164-01
|
$183,826
|
TONG, YOUZHI
|
ANGION BIOMEDICA CORPORATION
|
|
Orthotopic models of tumor angiogenesis and blood flow
|
5R44CA099258-03
|
$374,848
|
YANG, MENG
|
ANTICANCER, INC.
|
|
Alkylating Vitamin D Derivative
|
1R41CA126317-01A1
|
$258,398
|
CASTOR, TREVOR
|
APHIOS CORPORATION
|
|
Improving the Transfer of ERK siRNA Constructs Using Nanoporous Silica
|
1R41CA126155-01A1
|
$100,000
|
Landry, Christopher
|
APOLLO SRI, LLC
|
|
Drug-eluting Tracheobronchial Stents to treat Obstruction caused by Lung Cancer
|
1R43CA119503-01A2
|
$100,000
|
SHENOY, NARMADA
|
ARAVASC, INC.
|
|
SYNTHESIS OF NON-GMP SMALL MOLECULES
|
N02CM622024-002
|
$202,030
|
IONESCU, DUMITRU
|
Ash Stevens Inc
|
|
MANUFACTURE OF BULK CHEMICALS AND BULK PHARMACEUTICAL INGREDIENTS FOR PRECLINCAL
|
N02CM622016-003
|
$749,081
|
KASKIR, BASHIR
|
ASH STEVENS INC
|
|
Drug Delivery Carriers Targeted to Breast Tumor by Fusion Phage Proteins
|
1R01CA125063-01
|
$411,927
|
PETRENKO, VALERY
|
AUBURN UNIVERSITY AT AUBURN
|
|
Calpain Inhibitors for Cancer Related Neuropathies
|
1R43CA121653-01A1
|
$187,907
|
WEBB, ROBERT
|
AXONA, INC.
|
|
PRECLINICAL TOXICOLOGY AND PHARMACOLOGY OF DRUGS
|
N01CM422000-009
|
$801,062
|
JOHNSON, JERRY
|
BATTELLE MEMORIAL INSTITUTE
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-18
|
$480,000
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
Breast cancer response markers to a dual HER1/2 blocker
|
5R01CA112305-03
|
$252,236
|
CHANG, JENNY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Modeling Airway Lung Cancer and the Role of Inflammation
|
5U01CA105352-04
|
$863,870
|
DeMayo, Francesco
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel Oncolytic HSP Vaccine for Systemic Tumor Therapy
|
5R01CA100841-02
|
$206,823
|
HUANG, XUE
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Prostate Cancer
|
3P50CA058204-13S1
|
$1,124,001
|
ITTMANN, MICHAEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel Inhibitor of Stat3 for Prostate Cancer Therapy
|
5R01CA104035-03
|
$280,899
|
JING, NAIJIE
|
BAYLOR COLLEGE OF MEDICINE
|
|
RNAi-Based Therapy of Hepatocellular Carcinoma
|
5R01CA109574-03
|
$224,720
|
LI, KAIYI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cytokine Expression in LCH and Therapeutic Response
|
5R21CA114981-02
|
$232,676
|
MCCLAIN, KENNETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
1P30CA125123-01
|
$1,500,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-01S1
|
$111,700
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer
|
3P50CA058183-13S1
|
$153,479
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer
|
5P50CA058183-13
|
$2,612,827
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Small-molecule analysis of signaling pathways
|
5R01CA109277-03
|
$252,810
|
UESUGI, MOTONARI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targets of Vitamin D Receptor Action in Prostate
|
5R01CA107691-04
|
$292,538
|
Weigel, Nancy
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Biology and Diagnosis of HNPCC
|
5R01CA072851-12
|
$326,412
|
BOLAND, Clement
|
BAYLOR RESEARCH INSTITUTE
|
|
Arrayed Microfluidic Device for Reconstituted Tissue Assays
|
9R44CA133909-02
|
$528,122
|
HAYES, STEVEN
|
BELLBROOK LABS, LLC
|
|
Generic Fluorescent HTS Assay for Kinases and ATPases
|
5R44CA110535-03
|
$257,753
|
Lowery, Robert
|
BELLBROOK LABS, LLC
|
|
Development and Production of Parenteral Dosage Forms for Clinical Studies
|
N02CM037005-007
|
$817,092
|
SMITH, TIMOTHY
|
Ben Venue Laboratories Inc
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-24S1
|
$80,000
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-24
|
$391,000
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-09
|
$128,678
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Renal Cancer SPORE
|
5P50CA101942-05
|
$2,330,598
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting AR-NCoR Interaction in Prostate Cancer
|
1R01CA111803-01A2
|
$323,000
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Mechanisms of Hemidesmosome Disassembly: Role of a6b4 integrin phosphorylation
|
1R01CA120202-01A1
|
$290,700
|
RABINOVITZ, ISAAC
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Regulation and function of the PKC/PKD signaling pathway
|
5R01CA075134-09
|
$290,144
|
TOKER, ALEX
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Synergy between phytochemicals for prostate cancer prevention
|
1R03CA130133-01
|
$85,000
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Oldenlandia diffusa for prostate cancer treatment
|
1R21CA133865-01A2
|
$170,000
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
A novel biotherapeutic treatment for prostate cancer
|
1R43CA130228-01
|
$145,306
|
CHOI, ANTHONY
|
BEXION PHARMACEUTICALS, INC.
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|